The Cancer Biology program constitutes the foundation of basic science research of the OHSU Cancer institute. The overall goal of the Cancer Biology Program is to investigate the underlying cellular and molecular mechanisms involved in the development of cancer and in the regulation of both normal and abnormal cell growth. The scientific thrust of the program is in two related areas of investigation: Carcinogenesis/Genetic Instability and Signal Transduction. There are with 34 full and 2 associate members in the program with $25.1 million in grant funding stemming from 83 projects. Of these, 26 grants provide $7.4 million in NCI funding. Members of the Carcinogenesis/Genetic Instability group focus their studies around cell cycle control, the regulation of apoptosis, and the relationship of these events to the development of genetic instability and cancer. The members of the Signal Transduction group focus their studies around general signaling mechanisms of relevance to regulation of normal and cancer cell growth: the integrated function of growth factors and their receptors, kinase-mediated signaling phenomena, and the regulation of transcription that lies downstream of the aforementioned events. Because of the seamless nature of cellular regulation that is relevant to the cancer problem, there is a great deal of overlap between the research interests of the two groups. These shared interests have led to an abundance of collaborations and interactivity among the members of the Cancer Biology program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-10
Application #
7311034
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
10
Fiscal Year
2006
Total Cost
$9,640
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531

Showing the most recent 10 out of 277 publications